MedTrace Logo

Impact of Evolocumab on the Antiplatelet Effects of Ticagrelor and Aspirin in Patients With Acute Coronary Syndrome

NCT05418166 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2022-06-14

No results posted yet for this study

Summary

The aim of the present study is to investigate the effects of evolocumab in addition to statin therapy on platelet reactivity in patients with acute coronary syndrome (ACS) while on Ticagrelor and Aspirin treatment.

Conditions

  • Acute Coronary Syndrome

Interventions

DRUG

Evolocumab

evolocumab 140mg subcutaneous injection after regular take Ticagrelor and Aspirin for 5 days.

Sponsors & Collaborators

  • First Affiliated Hospital of Harbin Medical University

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-12-23
Primary Completion
2022-09-01
Completion
2022-09-01
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05418166 on ClinicalTrials.gov